Login to Your Account



Race to the Finish Line

Abbott Going Toe to Toe with Gilead in Oral HCV Regimen

By Marie Powers
Staff Writer

Monday, October 15, 2012
In recent months, Gilead Sciences Inc. appeared to be in the driver's seat in the race for an all-oral, interferon-free hepatitis C virus (HCV) regimen. However, Abbott's posting of the first Phase III trial of its combination HCV regimen on ClinicalTrials.gov puts Gilead on notice that it won't cross the finish line unchallenged.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription